Rhode Island Kidney Care Connection
Furthering Kidney Health for Patients
With Diabetes
|
Amlodipine/Benazepril Best for Slowing Progression of Chronic Kidney Disease
Medscape Today
Michael O'Riordan
Antihypertensive combination therapy with the angiotensin-converting enzyme (ACE) inhibitor benazepril plus the calcium-channel blocker amlodipine (Lotrel, Novartis) is more effective than treatment with the ACE inhibitor and a diuretic for slowing progression to chronic kidney disease (CKD), a new analysis shows [1]. After a mean follow-up of three years, amlodipine and benazepril significantly reduced the progression to CKD 48%, an absolute reduction of 1.7%, when compared with benazepril and hydrochlorothiazide.To sign in and view the full article, click here. |
FDA Approves First Generic Formulations of Losartan for Hypertension
Medscape Today
Yael Waknine
The US Food and Drug Administration (FDA) has approved the first generic formulations of losartan potassium tablets, alone and in combination with hydrochlorothiazide (Cozaar and Hyzaar, Merck & Company, Inc.), for the treatment of hypertension.
Losartan tablets have been approved in 25-mg, 50-mg, and 100-mg doses; losartan/hydrocholorothiazide combination tablets will be available in strengths of 50 mg/12.5 mg, 100 mg/12.5 mg, and 100 mg/25 mg (Teva Pharmaceuticals, USA). The 100 mg/12.5 mg losartan/hydrochlorothiazide formulation will also be manufactured by several other companies, including Mylan Pharmaceuticals Inc., Roxane Laboratories Inc., and Torrent Pharmaceuticals Ltd. According to FDA officials, the generic losartan products will carry the same safety concerns as their brand counterparts, including a boxed warning against usage during the second and third trimesters of pregnancy. To sign in and view the full article, click here. |
Innovative Approaches to Diabetes Management: Closed-Loop Insulin Delivery
Boris Gorsh
PharmD Candidate
The discovery of insulin in the 1920s stimulated progressive advancements in diabetes care. Before this time, the typical patient with diabetes was treated primarily by means of a strict diet - less than 500 calories per day, which eventually lead to either starvation or death from disease [1]. Since the first insulin extraction, a significant amount of work has gone into insulin utilization enabling it to become a life-saving therapy for millions of people. A new approach, called automated closed-loop (CL) insulin delivery, has recently emerged and may significantly impact the quality of care for patients with diabetes. This article will provide a description of the components of CL insulin delivery and review a recent trial on this topic. To view the full article, click here. |
|
|
This material was prepared by Quality Partners of Rhode
Island, the Quality Improvement Organization for Rhode Island, under
contract with the Centers for Medicare & Medicaid Services (CMS),
an agency of the U.S. Department of Health and Human Services.
|
|
|
The Fistula First Breakthrough
Initiative 2009 Annual Report
The Fistula First Breakthrough Initiative (FFBI) announces the release of their Annual Report of its achievements for 2009. The Annual Report focuses on achieving an increase in the prevalent AV fistula rate, developing a strategic plan, new tools and resources, and providing technical assistance. To view the full report, click here. |
|
Events &
Continuing Education
Opportunities
April 29
7:00 am
Providence Marriott Hotel
May is National High Blood Pressure Awareness Month and American Stroke Month
About 73 million people in the United States have high blood pressure, which is also called hypertension. High blood pressure increases the risk for heart disease and stroke, the first and third leading causes of death in the United States. To learn more, click here. |
Contact Us
For information or technical assistance on Quality Partners' Chronic Kidney Disease Project, please contact Lynn Pezzullo.
|
|
|
